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Abstract
Background: Malaria in Zambia remains a public health and developmental challenge, affecting mostly children
under five and pregnant women. In 2002, the first-line treatment for uncomplicated malaria was changed to
artemether-lumefantrine (AL) that has proved to be highly efficacious against multidrug resistant Plasmodium
falciparum.
Objective: The study objective was to determine whether dihydroartemisinin-piperaquine (DHA/PQP) had similar
efficacy, safety and tolerability as AL for the treatment of children with uncomplicated P. falciparum malaria in
Ndola, Zambia.
Methods: Between 2005 and 2006, 304 children (6-59 months old) with uncomplicated P. falciparum were
enrolled, randomized to AL (101) or DHA/PQP (203) and followed up for 42 days. Outcome of treatment was
defined according to the standard WHO classification, i.e. early treatment failure (ETF), late clinical failure (LCF, late
parasitological failure (LPF) and adequate clinical and parasitological response (ACPR). Recurrent infections were
genotyped to distinguish between recrudescence and new infection.
Results: No ETF was observed. At day 28, PCR-uncorrected ACPR was 92% in the DHA/PQP and 74% in the AL arm
(OR: 4.05; 95%CI: 1.89-8.74; p < 0.001). Most failure were new infections and PCR-corrected ACPR was similar in the
two study arms (OR: 0.69; 95%CI: 0.22-2.26; p = 0.33). Similar results were observed for day 42, i.e. higher PCR-
uncorrected ACPR for DHA/PQP, mainly due to the difference observed up to day 28, while the PCR-corrected
ACPR was similar: DHA/PQP: 93% (179/192), AL: 93% (84/90), (OR: 0.92; 95%CI: 0.30-2.64; p = 0.85). Except for cough,
more frequent in the DHA/PQP arm (p = 0.04), there were no differences between treatment arms in the
occurrence of adverse events. Two serious adverse events were probably associated to AL treatment.
Conclusion: DHA/PQP was as efficacious, safe and well tolerated in treatment of uncomplicated malaria as AL,
though in the latter group more new infections during the follow up were observed. DHA/PQP seems a potential
candidate to be used as an alternative first-line or rescue treatment in Zambia.
Trial Registration: ISRCTN16263443, at http://www.controlled-trials.com/isrctn
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In Zambia, chloroquine (CQ) has been for a long time
the first-line treatment of uncomplicated malaria [1].
Reduced in vivo CQ sensitivity was first reported in
1978 [2] and CQ resistance in 1983 [3]. In 1996, sulpha-
doxine-pyrimethamine (SP) was recommended by the
malaria control programme as rescue treatment if CQ
failed [4]. Between 1996 and 2000, CQ and SP in vivo
tests in children under the age of five conducted in ele-
ven malaria sentinel sites showed that CQ resistance
(based on 14 days follow up) was as high as 52% in
some areas (range: 12.8-52.0%). In 1998, in the Western
Province, parasitological resistance (RII-RIII) to CQ (7-
day follow up) was 60% and that to SP 26% (14-day fol-
l o wu p ) ,af i g u r eh i g h e rt h a np r e v i o u s l yr e p o r t e d[ 5 ] ,
raising concerns about the efficacy of the recently-
introduced SP as it was the rescue treatment in case of
CQ treatment failure. By 2000, some neighbouring
countries like Kenya, Malawi, South Africa, Tanzania,
Botswana and Zimbabwe had changed their first-line
treatment for uncomplicated malaria from CQ to SP [6].
Considering the high resistance to CQ and SP and the
WHO recommendation in 2001 to use artemisinin-
based combination therapy (ACT) to combat drug resis-
tant falciparum malaria [7], the Zambian Ministry of
Health (MoH) decided in 2002 to adopt artemether-
lumefantrine (AL) as first-line treatment for uncompli-
cated Plasmodium falciparum malaria [1,8]. AL was
recommended despite concerns at that time over its use
in pregnant women and children under 10 kg, the need
of a fatty meal for the optimal absorption of lumefan-
trine, the short shelf life (2 years), its sustainability and
cost. Indeed, it was estimated that the cost of AL
needed to treat all malaria cases would exceed the total
MoH allocation for basic health care [1]. Few alterna-
tives were available [1] and since there were no data on
AL use in Zambia, pharmacovigilance to monitor its tol-
erance was recommended. Nevertheless, AL was
deployed as first line drug with remaining concerns
whether sufficient health staff had been trained on its
use and the risk of a vertically oriented approach as
opposed to strengthening the health service provision.
During this transition period, between 2003 and 2005, a
clinical trial carried out in Ndola on adult patients
showed that AL was significantly more efficacious than
SP [9]. In 2005, a study comparing dihydroartemisinin-
piperaquine (DHA/PQP) with AL for the treatment of
uncomplicated P. falciparum malaria in children was
carried out in Ndola. This was part of a phase III multi-
centre study done, besides Zambia, in four other African
countries (Burkina Faso, Kenya, Mozambique and
Uganda) [10]. More detailed results of the Zambian
study are presented below.
Methods
Study site and population and design
The study (randomized and open-label) was conducted
between September 2005 and May 2006 in Ndola,
Zambia, where four peri-urban health centres (Chifubu,
Chipulukusu, Lubuto and Masala) were identified for
the recruitment of the patients. The study was spon-
sored by the Sigma-Tau, Industrie Farmaceutiche
Riunite, Italy, and funded by Medicines for Malaria
Venture (MMV). In Zambia, in 2006, malaria prevalence
in children under five was on average 22% [11]. In
Ndola, the malaria incidence (confirmed and suspected
cases) estimated with the information collected by the
health management information system (HMIS) was
44.9% (449/1,000) in 2005 and 28.0% (280/1,000) in
2009, showing a marked decline over a relatively short
period [12]. In this peri-urban study area, the malaria
endemicity is mesoendemic. It has a seasonal transmis-
sion which peaks between November and May.
Study procedures
Children 6-59 months old attending the health facilities
with suspected malaria were included if they fulfilled the
following inclusion criteria: body weight >5 kg; microsco-
pically confirmed P. falciparum mono-infection with asex-
ual parasite densities between 2,000 and 200,000/μl; fever
(axillary temperature ≥37.5°C) or history of fever in the
preceding 24 h. Patients were not recruited if they met at
least one of the following exclusion criteria: severe malaria
or other danger signs; acute malnutrition (weight for
height <70% of the median National Center for Health
Statistics/WHO reference) [13,14] or any other concomi-
tant illness or underlying disease; contra-indication to
receive the trial drugs or history of treatment with any
anti-malarial drug or drug with anti-malarial activity
within the 14 days preceding enrolment. Patients satisfying
the inclusion/exclusion criteria were enrolled if the parent/
guardian signed a detailed written informed consent trans-
lated in local language, Bemba.
Patients were individually randomized according to a
2:1 (DHA/PQP:AL) scheme so as to have more patients
in the DHA/PQP arm to provide better estimates for its
cure rates and more cases for the integrated safety data
base. A total of 304 study participants were enrolled.
A randomization list was generated by an independent
off site contract research organization (CRO), with
each treatment allocation concealed in opaque sealed
e n v e l o p e st h a tw e r eo p e n e do n l ya f t e rt h ep a t i e n t ’s
recruitment.
Both drugs were co-formulated, fixed-dose ACTs and
they were administered under direct supervision during
three consecutive days, according to the patient’sb o d y
weight. AL (Coartem™,N o v a r t i s ,S w i t z e r l a n d )w a s
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Page 2 of 9administered twice a day (at enrolment and at 8, 24, 36,
48 and 60 h) according to the following dosage: weight
5-14 kg: one tablet per dose; weight 15-24 kg: two
tablets per dose; weight 25-34 kg: three tablets per dose.
DHA/PQP (Eurartesim™, Sigma-Tau, Italy) was given
once daily, at the standard dosage of 2.25 mg/kg and
18 mg/kg per dose of DHA and PQP, respectively,
rounded up to the nearest half tablet. To facilitate the
correct dosing of DHA/PQP, two formulations were
used (DHA 20 mg + PPQ 160 mg and DHA 40 mg +
PPQ 320 mg). In case of vomiting, a full dose was
repeated if this occurred within the first half an hour or
half a dose if it occurred between 30 minutes and 1 h.
In agreement with the instruction of the manufacturer,
AL was administered concomitantly with milk to facili-
tate the absorption of lumefantrine, while DHA/PQP
was administered only with some water. For infants,
drugs were crushed, mixed with water and administered
as slurry. In order to minimize bias, treatment allocation
was concealed until recruitment of the patient was com-
pleted. Both patient allocation to the different analysis
populations and assessment of the primary end-point
were made by staff blinded to the treatment assignment
and before availability of the PCR results.
Ethical considerations and patient safety
The study was approved by a local institutional ethics
committee (Tropical Diseases Research Centre Ethics
Committee) and the ethical and scientific committee of
the Institute of Tropical Medicine, Antwerp, Belgium.
The trial was conducted under the provisions of the
Declaration of Helsinki (2002) and in accordance with
Good Clinical Practices guidelines set up by the Interna-
tional Conference on Harmonization. A Study Steering
Committee, a Data Monitoring Committee and a Clini-
cal Development Committee were created prior to the
beginning of the trial, and worked independently to har-
monize and monitor the study. The trial was registered
prior to the enrolment of the first patient in the Interna-
tional Standard Randomized Controlled Trials Register,
number ISRCTN16263443, at http://www.controlled-
trials.com/isrctn.
Treatment follow-up, clinical and laboratory procedures
All children were kept at the health facility for the three-
day dosing period. The mother/guardian was asked to
return with the child for scheduled visits on days 7, 14,
21, 28, 35 and 42 post-treatment, or if any symptoms
occurred. Field workers traced patients missing any visit.
For each visit, a physical examination was performed by
the study clinicians, vital signs were recorded and axillary
temperature measured with an electronic thermometer.
Adverse events and serious adverse events were recorded
and monitored throughout the study.
The study was monitored by an external CRO who
carried out visits on a monthly basis. Rescue treatment
for recurrent parasitaemia was quinine 10 mg/kg orally
three times a day for 7 days. All participants received a
free insecticide-treated bed net at recruitment.
Capillary or venous blood was taken at every visit.
Thick and thin blood films were prepared, dried and
Giemsa-stained, and parasite density estimated by
counting the number of asexual parasites in 200 white
blood cells (WBC), assuming a standard WBC count of
8,000/μl. In addition, quality control was performed on
20% of all the slides at a central laboratory. Samples for
haematology (full blood count) and biochemistry (liver
and renal function) were taken at enrolment, at days 3,
28 and 42, and at any other visit if judged necessary by
the clinician. For PCR analysis, three blood spots were
collected on filter paper (Whatmann 3 MM) at enrol-
ment and at any visit after day 7. Each filter paper was
dried and individually stored in a plastic bag containing
silica gel. All filter papers were subsequently transferred
to the Institute of Tropical Medicine (Antwerp,
Belgium) where centralized genotyping was conducted.
Purification of DNA was conducted as previously
described [15]. Three polymorphic genetic markers
MSP1, MSP2 and GluRP were used to distinguish recru-
descence from new infections (PCR-corrected). Recru-
descence was defined as at least one identical allele for
each of the three markers in the pre-treatment and
post-treatment samples. New infections were diagnosed
when all alleles for at least one of the markers differed
between the two samples. All gels were re-read under
blinded conditions by an independent expert (National
Museum of Natural History, Paris, France). In addition,
20% of the filter papers were re-analysed and assessed
by an independent laboratory (Shoklo Malaria Research
Unit, Mae Sot, Thailand).
Outcome classification
Treatment outcome was established according to stan-
dard WHO classification [16]: Early Treatment Failure
( E T F )w a sd e f i n e da so n eo ft h ef o l l o w i n g :i )d a n g e r
signs or severe malaria on days 1, 2 or 3 with parasitae-
mia; ii) parasite density at day 2 greater than at day 0;
iii) parasitaemia on day 3 with axillary temperature
≥37.5°C and iv) parasite density at day 3 equal or greater
than 25% of that at day 0. Late Clinical Failure (LCF)
was defined as danger signs or severe malaria or parasi-
taemia with axillary temperature ≥37.5°C between day 4
and day 28 (or 42), without having been previously clas-
sified as ETF. Late parasitological failure (LPF) was
defined as the reappearance of parasitaemia between day
4 and day 28 (or 42) without fever and without pre-
viously meeting any of the criteria for ETF or LCF. An
adequate clinical and parasitological response (ACPR)
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42) without previously meeting any of the criteria for
ETF, LCF and LPF. The number of cases of total treat-
ment failure (TTF) was computed as ETF+LCF+LPF.
More detailed analysis of the outcome classification can
be found in Table 1.
Statistical analysis
The primary endpoint was the PCR-corrected adequate
clinical and parasitological response (ACPR) at day 28;
secondary efficacy outcomes included PCR-corrected
cure rates at day 42, PCR-uncorrected cure rates at
days 28 and 42; parasite and fever clearance times, pre-
sence and clearance of gametocytes, and haemoglobin
(Hb) recovery from baseline to day 28. All standard
safety outcomes such as incidence of adverse events,
changes from baseline on haematology and clinical
chemistry parameters and vital sign variation during the
study were also evaluated. The treatment outcome was
analysed as per protocol analysis based purely on the
standard definitions of early/late clinical and parasitolo-
gical failure [16] (Table 1). All cases not strictly match-
ing the WHO definitions and/or the described
procedure were reviewed individually at the data review
meetings.
Serious Adverse Events (SAE) were defined using the
ICH GCP guidelines as any untoward medical occur-
rence that at any dose resulted in death, was life threa-
tening, required hospitalization or prolongation of
existing hospitalization, resulted in persistent or signifi-
cant disability/incapacity.
This is a sub-analysis of a multicentre study designed
as a non-inferiority trial. This study, being part of a
multicenter clinical trial, was not powered to compare
treatments within Zambia. All randomized patients ful-
filling the protocol eligibility criteria, having taken at
least 80% of the study medication, having completed the
day-28 assessment and having an evaluable PCR in case
of recurrent parasitaemia were included. All drop-outs
and all patients with missing or non-interpretable PCR
results were excluded from the PP population. Data was
entered using SAS programme. Statistical analysis was
done using Epi Info software version 3.4.3 and STATA
statistical analysis software package (version 10; Stata
Corp.). An univariate analysis was done to characterize
the sample of patients in the study. To determine the
risk of treatment failure, proportions were compared
using the c2o rF i s h e r ’s exact test. A two sided p-value
of ≤0.05 was defined as statistical significant. In the pro-
portional hazard regression, all patients were censored
Table 1 Day 28 and Day 42 uncorrected ACPR (steps 1-11) and PCR-corrected ACPR (steps 1-16) in the different
populations of analysis
Step Event to be assessed Per Protocol Pure ITT
1 Withdrawal BEFORE OR AT D28: any reason except lost to follow-up Depending on reason, a
patient can be excluded or
evaluated as Failure
Failure
2 Withdrawal BEFORE OR AT D28: lost to follow-up Excluded Failure
3 * Withdrawal AFTER D28: any reason except lost to follow-up Failure Failure
4 * Withdrawal AFTER D28: lost to follow-up Failure Failure
5 ETF, LCF, and LPF in accordance with the WHO criteria Failure Failure
6** Presence of major protocol violations Excluded No effect
7** Occurrence of adverse events highlighting recurrence of malaria Failure Failure
8** Presence of missing parasitaemia at two or more consecutive scheduled visits or presence
of an isolated missing parasitaemia not preceded and followed by a negative parasitaemia
Failure Failure
9** Administration of drugs with a known or suspected anti-malaria action as rescue treatment Failure Failure
10** Administration of drugs with a known or suspected anti-malaria action as non rescue
treatment
Excluded Failure
11** Administration of anti-malarial drugs for Plasmodium vivax, Plasmodium malariae, or
Plasmodium ovale during the course of the study in patients not classified as ETF or LTF
Failure with new infection Failure with
new infection
12 PCR not done BETWEEN DAY 4 AND DAY 13 Recrudescence Recrudescence
13 PCR: non interpretable or missing or not done BETWEEN DAY 14 AND D28 Excluded Recrudescence
14** PCR: non interpretable or missing or not done AFTER D28 Rule *** Recrudescence
15 PCR = new infection or uncorrected ACPR = Failure with new infection Success Success
16 PCR = recrudescence Recrudescence Recrudescence
* For the Day 42 endpoint.
** All such cases were individually revised at the Blind Data Review meeting. Protocol violations were pre-defined.
*** Patients for whom the PCR is not interpretable or missing will be assigned the result “recrudescence” or “new infection” according to the ratio between these
at the corresponding time point and within each treatment group, separately considered.
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tion was used to define failure or ACPR (Table 1). The
risk of new infections was compared to the other
outcomes.
Results
Baseline characteristics and trial profile
Among 3,325 potential patients attending the 4 health
facilities, 733 were within the required age, had fever (or
history of fever) and peripheral parasitaemia by micro-
scopy. Nevertheless, 429 were not included because the
parasite density was outside the required range (49.0%),
refused to take part in the study (30.3%), had taken an
anti-malarial before screening (5.8%), were coming out-
side the study site (3.5%) or other (11.4%) (Figure 1). In
total, 304 patients were enrolled, 203 were in the DHA/
PQP arm and 101 in the AL arm. At enrolment, the two
groups had similar demographic and clinical characteris-
tics (Table 2). Out of the 304 study participants
enrolled, 290 (95.4%) completed the follow-up until day
42. The percentage of patients lost to follow up was sta-
tistically similar between the two study arms respectively
3.5% (7/203) in the DHA/PQP and 7.0% (7/101) in the
AL arm (p = 0.08). Parents of one patient in the DHA/
PQP arm withdrew consent, 3 in the DHA/PQP arm
and 4 in the AL arm were excluded from the analysis
after having wrongly received an anti-malarial drug dur-
ing follow up in absence of a microscopically confirmed
malaria infection or after vomiting twice the study medi-
cation. In the end 282 patients, 192 in the DHA/PQP
arm and 90 in the AL arm, were used for the per proto-
col analysis.
Clinical and parasitological outcomes
No ETF was observed. At day 14, the ACPR for both
arms was 100%. At day 28, the percentage of patients
with recurrent infection was significantly lower in the
DHA/PQP (7.8%, 15/192) as compared to the AL
group (25.6%, 23/90) (OR: 0.25; 95%CI: 0.11-0.53; p <
0.001). This difference was seen for both the LCF
(3.1% vs. 11.1%; OR: 0.26; 95%CI: 0.08-0.80; p = 0.007)
and LPF (4.7% vs. 14.4%; OR: 0.29; 95%CI: 0.11-0.77;
p = 0.004) (Table 3). Therefore, the PCR-uncorrected
ACPR was 92.2% in the DHA/PQP and 74.4% in the
AL arm (OR: 4.05; 95%CI: 1.89-8.74; p < 0.001). How-
ever, according to the PCR analysis, most treatment
failures were due to new infections and were signifi-
cantly less frequent in the DHA/PQP group (3.1%,
6/192) as compared to the AL (18.9%, 17/90) (OR:
0.14; 95%CI: 0.05-0.39; p < 0.001). Recrudescence was
low, 4.7% (9/192) vs. 6.7% (6/90) for DHA/PQP and
AL, respectively, and not statistically different between
the two study arms (OR: 0.69; 95% CI: 0.22-2.26;
p = 0.33).
At day 42, the percentage of patients with a recurrent
infection was lower in the DHA/PQP (21.9%, 42/192)
than the AL group (36.7%, 33/90) (OR: 0.48; 95%CI:
0.27-0.87; p = 0.009). Such difference was mainly due to
a lower proportion of LCF in the DHA/PQP group
compared to AL group (5.8% vs. 14.4%; OR: 0.36; 95%
CI: 0.14-0.90; p = 0.014), while the proportion of LPF
did not differ between the two study arms (16.1% vs.
22.2%; OR: 0.67; 95%CI: 0.34-1.32; p = 0.22). As for the
estimation at day 28, most recurrent infections were
new infections, significantly less in the DHA/PQP
(15.1%, 29/192) than in the AL (30.0%, 27/90)group
(OR: 0.42; 95%CI: 0.22-0.79; p = 0.003) (Table 3). Such
difference occurred mainly within the first 28 days as
afterwards the occurrence of new infections was similar
between the two study groups (12.0% vs. 11.1%). Only
four recrudescences were observed after day 28, all of
them in the DHA/PQP group. The PCR-corrected
3325
Total Screened
733
Total Positive
210 Parasitemia outside range
130 Refused consent
25 Taken antimalarial
15 From outside study area
49 Others
304
Enrolled
203
Randomised to DHA-
PPQ
101
Randomised to AL
Day3-28
4 Withdrawn
7 Lost to follow-up
Day29-42
None withdrawn
No lost to follow-up
Total completed study
192
Day3-28
4 Withdrawn
7 Lost to follow-up
Day29-42
None withdrawn
No lost to follow-up
Total completed study
90
TRIAL
PROFILE
Figure 1 Trial profile.
Table 2 Baseline characteristics of patients by treatment
Characteristic DHA/PQP AL
Number of patients 203 101
Number of females (%) 86 (42.4) 42 (41.2)
Mean weight in kg (±SD) 11.2 (2.5) 11.7 (2.7)
Mean age in months (±SD) 29.0 (14.1) 31.3 (13.8)
Median parasite density/μL (range) 35840
(14680-77520)
39120
(16600-86400)
Mean haemoglobin in g/dL (±SD) 8.9 (1.7) 9.2 (1.8)
The differences in the baseline characteristics between the treatment groups
are not significant.
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PQP: 93.2% (179/192), AL: 93.3% (84/90), (OR: 0.92;
95%CI: 0.30-2.64; p = 0.85).
Parasite clearance was rapid in both treatment groups
(Kaplan-Meier estimate of median time was 2 days in
each group, in both populations). About 60% of patients
had fever at baseline while at day 2 more than 97% of
patients were afebrile in both treatment groups. Game-
tocyte prevalence at recruitment was similar in both
study arms (ITT: DHA-PQP 11.75%; AL 12.94%, p =
0.501; PP: DHA-PQP 11.55%; AL 13.36%, p = 0.326).
However, gametocyte carriage measured as rate of per-
son-gametocyte-weeks was significantly higher in the
DHA-PQP group than in the AL group, both for the
ITT (DHA-PQP: 43.97/1,000; AL: 21.43/1,000; p =
0.005) and the PP (DHA-PQP: 42.65/1,000; AL: 21.23/
1,000; p = 0.006) populations.
In patients with no recurrent parasitemia, hemoglobin
was increased at day 28 in both DHA-PPQ arm (+1.39 g/
dL; 95%CI: 1.13-1.66; p < 0.0001) and AL (+0.89 g/dL; 95%
CI: 0.48-1.31; p < 0.0001) and was different between treat-
ment groups (p = 0.047). In patients with no recurrent
parasitemia, hemoglobin was increased at day 42 in both
DHA-PPQ arm (+1.91 g/dL; 95%CI: 1.23-1.86; p < 0.0001)
and AL (+1.45 g/dL; 95%CI: 0.95-1.71; p < 0.0001) and was
not different between treatment groups (p = 0.45).
At day 28 the survival analysis, using the ITT defini-
tion, showed a hazard Ratio (HR) (DHA/PQP/AL) of 0.35
for PCR-uncorrected treatment failure (95%CI: 0.21-0.62;
p < 0.0001) (Figure 2), 0.17 for new infections (95%
CI:0.07-0.43; p < 0.0001) (Figure 3) and 0.60 that for true
failures (recrudescence) (95%CI: 0.34-1.40; p = 0.31)
(Figure 4). The survival analysis till day 42 showed a HR
of 0.55 (DHA/PQP/AL) for PCR-uncorrected treatment
failure (95%CI: 0.37-0.82; p = 0.004) (Figure 2), 0.47 for
new infections (95%CI: 0.28-0.79; p = 0.005) (Figure 3)
and 0.70 for true failures (recrudescence) (95%CI: 0.36-
1.34; p = 0.29) (Figure 4).
Adverse events
Seven serious adverse events (SAE) were observed: three
of them for patients (two in DHA/PQP and one in AL)
having prolonged hospitalization due to late fever clear-
ance; in addition, in the DHA/PQP group, one patient
developed severe malaria and another had persistent
Table 3 PCR-adjusted and unadjusted treatment outcomes by days 28 and 42
DHA/PQP (N = 192) n (%) AL (N = 90) n (%) Odds Ratio (95% CI) p-value
PCR-unadjusted
Day 28
LCF 6 (3.1) 10 (11.1) 0.26 (0.08-0.80) 0.007
LPF 9 (4.7) 13 (14.4) 0.29 (0.11-0.77) 0.004
ACPR 177 (92.2) 67 (74.4) 4.05 (1.89-8.74) <<0.001
Day 42
LCF 11 (5.8) 13 (14.4) 0.36 (0.41-0.90) 0.014
LPF 31 (16.1) 20 (22.2) 0.67 (0.34-1.32) 0.217
ACPR 150 (78.1) 57 (63.3) 2.07 (1.15-3.71) 0.009
PCR-adjusted
Day 28
LCF 0 (0) 3 (3.3)
LPF 9 (4.7) 3 (3.3)
ACPR 183 (95.3) 84 (93.3) 1.45 (0.44-4.64) 0.33*
Day 42
LCF 4(2.1) 3(3.3)
LPF 9(4.7) 3(3.3)
ACPR 179 (93.2) 84 (93.3) 0.98 (0.32-2.90) 0.974
*Fisher exact p values.
Figure 2 Cumulative Hazard estimates for PCR-unadjusted
treatment failure on day 42 by treatment group, Zambia, 2009.
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quinine. In the AL group, one patient developed severe
anaemia on day 3, possibly associated with study drug,
and was treated with quinine and blood transfusion; the
other patients had jaundice on day 3, possibly associated
to study drug. All patients recovered completely. No
deaths were observed during the study.
Both treatments were generally well tolerated and
most adverse events were associated with the disease
during the initial clinical episode or to the recurrent
parasitemia during the follow-up. Cough, attributed to
respiratory tract infections, was significantly more fre-
quent in the DHA/PQP arm than the AL arm while
diarrhoea was of borderline significance (Table 4).
Discussion
Both DHA/PQP and AL were highly efficacious in treat-
ing uncomplicated malaria in Zambian children, even if
statistically significant differences in favour of DHA/
PQP were observed for the uncorrected ACPR (for LPF
the difference was statistically significant only at D28).
In addition, the rate of recurrent infections, particularly
within the first 28 days of follow up, was significantly
higher in children treated with AL. One of the strengths
of this study is that it was done in an area of meso-
endemic malaria, in children under five, a high risk
group, and had a prolonged follow-up period of 42 days
not to miss late recrudescences and to reflect the term-
inal half-lives of the drugs [16]. One of the limitations
w a si tw a sn o tb l i n d e ds ot h a ta ni n f l u e n c eo nt h ee v a -
luation of the tolerability cannot be excluded. In terms
of robustness of the trial, this weakness was mitigated
with a blinded randomization procedure.
In this study, patients treated with DHA/PQP had
fewer re-infections, an added advantage as it allows
patient haematological recovery before a new infection
sets in, especially in high transmission areas. The with-
drawal and lost to follow-up rate (7%) were within the
WHO recommended limits [16]. There are few studies
that have compared these two forms of fixed-dose ACT.
One study in Tanzania reported P. falciparum multi-
drug resistant genes, which were weakly and indirectly
associated with a decreased in vitro susceptibility to
lumefantrine [17], indicating that resistance may emerge
for the long acting partner drugs of the artemisinin deri-
vative. In one Rwandan study, DHA/PQP was well-toler-
ated and highly efficacious against multidrug resistant P.
falciparum [18]. Another study in Uganda reported
similar findings, with both drugs (DHA/PQP and AL)
having good efficacy and tolerability [19] Similarly, in a
study carried out in Papua Indonesia, half of the patients
presented with recurrent parasitaemia by day 42, mostly
due to re-infections [20]. The difference in re-infections
in this study and most studies could be explained by the
pharmacokinetic properties of piperaquine which has a
longer half-life (2-3 weeks) than lumefantrine (4-10
days) [21,22]. Indeed, long acting partner drugs provide
protection after initial treatment and can reduce the risk
of re-infection in high transmission areas, which, per se,
can be seen as a substantial help for the national health
Figure 3 Cumulative Hazard estimates of re-infection by day
42 by treatment group, Zambia, 2009.
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Figure 4 Cumulative Hazard estimates of recrudescence by day
42 by treatment group Zambia, 2009.
Table 4 Proportions of adverse events by treatment
group during follow-up
DHA/PQP
(N = 199)
AL
(N = 100)
p- Value
Anorexia 6.8% 8.3% 0.24
Cough 21.2% 15.4% 0.04
Diarrhoea 7.1% 3.8% 0.051
Fever 12.0% 14.4% 0.32
Respiratory tract infections 11.1% 8.7% 0.20
Vomiting 2.6% 3.8% 0.29
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Page 7 of 9care system. Nevertheless, the persistence of the drug at
sub-optimal therapeutic doses may lead to selection of
drug resistant parasites [19]. Even in Ndola, where
malaria is mesoendemic, the risk of new infections was
high, with the potential of selecting resistant parasites
[23]. Such theoretical risk, common for all forms of
ACT in which one of the components is a long-lasting
anti-malarial drug, may be reduced by the use of several
ACTs as first-line treatment. This could be feasible as
the number of ACTs available today would allow such
approach. Finally, a malaria episode occurring a few
weeks after treatment, be it a recrudescence or re-infec-
tion, is perceived by both the health care providers and
the users (patients and families) as another attack need-
ing another course of anti-malarials. From this point of
view, employing a treatment with a long post-treatment
prophylactic effect could be an advantage.
Both drugs are co-formulated but AL should be admi-
nistered twice a day for three days whilst DHA/PQP is
given once a day for three days. Furthermore, AL should
be administered with a fatty meal for an effective absorp-
tion of lumefantrine. In Zambia, where 80% of the popu-
lation is under the poverty level, the staple diet is based
on maize [24], it is difficult to provide a fatty meal for
patients before the intake of the drug. This could result
in a lower adherence or/and sub-optimal therapeutic
doses for AL compared to DHA/PQP. The unsupervised
treatment of DHA/PQP and AL has already been shown
to be as effective as the supervised treatment [25,26]. As
this study assessed the efficacy, it would be interesting to
know the effectiveness of these two drugs.
In summary, DHA/PQP may be a good alternative to
AL [19], but there are still some questions in the context
of public health distribution of millions of treatments,
about safety (Phase IV), effectiveness, sustainability and
cost of newly available forms of ACT, such as DHA/PQP
[27]. Furthermore, as the post-treatment prophylaxis is
most important in areas of high malaria transmission
with a high re-infection rate, the deployment of these
new fixed-dose combinations should not necessarily be
generalized, rather done according to the local character-
istics [18,19].
Conclusion
Considering the above challenges, the direct and indirect
costs, and the lessons learnt from the current treatment
policy change, DHA/PQP could be employed as rescue
and/or alternative treatment to AL or as second-line treat-
ment for patients re-attending the health facility with
malaria a few weeks after receiving the first line treatment.
This would be a major improvement as compared to the
current policy of administering quinine to any suspected
case of failure, a policy against the WHO recommenda-
tions to use an alternative ACT for the second-line
treatment [28]. It would also reserve quinine for the treat-
ment of severe malaria cases. This strategy would limit the
impact on the current treatment policy as DHA/PQP
would be introduced smoothly into the health system
without changing the first line treatment. If effectiveness
and cost-effectiveness studies turn out in favour of the
DHA/PQP combination, a switch between AL and DHA/
PQP as first-line therapy can still be debated and imple-
mented depending on the malaria endemicity. Whatever
the case, DHA/PQP is a credible option to be included in
the anti-malarial treatment policy in Zambia.
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